Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Which TB test works best for HIV patients? new study aims to find out

NCT ID NCT04926922

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Sep 02, 2026 · Updated 9 times

Summary

This study looked at 200 people living with HIV in Liberia to compare two tests for latent tuberculosis (TB) infection: a blood test (IGRA) and a skin test (TST). The goal was to see which test works better in this population. Participants had a skin test and their results were checked after 2-3 days. Those with a positive result got a chest X-ray and were referred for care if needed. The study is complete and aims to improve TB screening in Liberia.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help identify the best screening method for latent TB in people with HIV, leading to better prevention and care in Liberia.
What could go wrong
This is an observational study comparing existing tests, not testing a new treatment. Results may not apply to other populations or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

200 people

The number who actually took part.

Started

Jul 2021

Finished

Apr 2026

Lead sponsor

A government research agency

The lead sponsor is the US National Institutes of Health.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult participants must be enrolled in the main HONOR study of people living with HIV in Liberia who participated in the HONOR TB study at their Month 12 visit and tested positive on IGRA and/or TST.

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

* INCLUSION CRITERIA: In order to be eligible to participate in this study, an individual must meet all of the following criteria: * Be a participant on the PREVAIL VIII/HONOR study. * Be at least 18 years of age. * Be scheduled to undergo or have undergone IGRA at a Month 12 HONOR study visit. * Ability to return to the clinic 48 to 72 hours after TST placement for reading. * Ability to provide informed consent. In order to be eligible to participate in the extension phase of the study, an individual must meet all of the following criteria: * Participated in the PREVAIL VIIIa HONOR TB study. * Have had a positive TB test result on the TST and/or IGRA performed as part of the PREVAIL VIII HONOR or PREVAIL VIIIa HONOR TB study(ies). * Ability to provide informed consent. EXCLUSION CRITERIA: An individual who meets any of the following criteria will be excluded from participation in this study: * Received BCG vaccine \<=10 years prior. * Known hypersensitivity or allergy to any component of the PPD product. * Previous severe reaction (e.g., necrosis, blistering, ulcerations, or anaphylactic shock) to a TST. * Documented active TB or a clear history of treatment for latent infection or active disease. * Extensive burns or eczema or other skin conditions on the forearms that could affect placement and reading of the TST. * Pregnant or lactating women. * Any condition that, in the opinion of the investigator, would compromise the safety of the study participant or staff, or would prevent proper conduct of the study. An individual who meets any of the following criteria will be excluded from participation in the extension phase of this study: * Pregnant women. * Contraindication to CT scanning. * Any condition that, in the opinion of the investigator, would compromise the safety of the study participant or staff, or would prevent proper conduct of the study. Exclusion of Special Populations (Children, Adults Who Lack Capacity to Consent, and Pregnant Women) -We are able to obtain knowledge about TST performance in Liberia without exposing children, adults who lack capacity to consent, and pregnant women to the potential risk of reactions to the TST or exposure to radiation for research purposes.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • C.H. Rennie Hospital

    Kakata, Liberia

  • Duport Road Clinic

    Monrovia, Liberia

  • JFK Medical Center

    Monrovia, Liberia

  • National Institutes of Health Cinical Center

    Bethesda, Maryland, 20892, United States

  • Redemption Hospital

    Monrovia, Liberia

More trials for these conditions

Other studies related to the condition(s) this trial covers.